Glucagon II pp 451-465 | Cite as

Glucagon in Human Endocrine and Exocrine Disorders

  • A. M. Lawrence
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 66 / 2)

Abstract

In 1972, I prepared an article entitled “Pancreatic alpha-cell function in miscellaneous clinical disorders” (Lawrence 1972). In that chapter it was noted that, despite the enthusiastic search for and desire to implicate abnormalities of pancreatic glucagon secretion in the cause of certain human diseases, with the exception of the glucagonoma syndrome, glucagon’s causal role in other diseases remained elusive. A decade later, it is still uncertain whether abnormally high levels of measured glucagon in the blood of some individuals with, for example, acromegaly, hyperparathyroidism, or pheochromocytoma, reflect a general endocrine hypersecretory state akin to what has been described in the multiple endocrine neoplasia (MEN) syndrome or whether glucagon contributes causally to such endocrinopathies. Inrpretive uncertainties arise, in some part, from our less than perfect ability to measure pancreatic glucagon in bodily fluid or from our inability to interpret accurately what such measurements actually reflect in terms of the pathogenesis of associated disease entities in humans. As an example, radioimmunoassay measurements of glucagon from peripheral blood provide glucagon measurements after substantial hepatic extraction (see Chap. 40) and, in general, measure glucagon of several origins (see Chap. 11). In what follows, however, an attempt has been made to update previous observations which appear to involve glucagon in disordered endocrine and exocrine physiology.

Keywords

Lipase Cortisol Neuropathy Arginine Trypsin 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Aguilar-Parada E, Eisentraut AM, Unger RH (1969) Pancreatic glucagon secretion in normal and diabetic subjects. Am J Med Sci 257: 415–419PubMedCrossRefGoogle Scholar
  2. Avioli LV, Birge S J, Scott S, Shieber W (1969) Role of the thyroid gland during glucagon-induced hypocalcemia in the dog. Am J Physiol 216: 939–945PubMedGoogle Scholar
  3. Baetens D, Malaisse-Lagae F, Perrelet A, Orci L (1979) Endocrine pancreas: three dimensional reconstruction shows two types of islets of Langerhans. Science 206: 1323–1325PubMedCrossRefGoogle Scholar
  4. Baily CJ, Flatt PR, Atkins TW, Best LC, Matty A J (1975) Immunoreactive insulin in pancreatic juice and bile of rats. Diabetologia 11: 330–331Google Scholar
  5. Bloom SR (1972) An enteroglucagon tumor. Gut 13: 520–523PubMedCrossRefGoogle Scholar
  6. Bolli G, De Feo P, Compagnucci P, Cartechini MG, Angeletti G, Santeusanio F, Brunetti P, Gerich JE (1983) Abnormal glucose counterregulation in insulin-dependent diabetes mellitus. Interaction of anti-insulin antibodies and impaired glucagon and epinephrine secretion. Diabetes 32: 134–141Google Scholar
  7. Bornstein J, Reid E, Young FG (1951) The hyperglycaemic action of blood from animals treated with growth hormone. Nature 168: 903–905PubMedCrossRefGoogle Scholar
  8. Breuer RI, Zuckerman L, Hauch TW, Green W, O’Gara P, Lawrence AM, Foà PP, Matsuyama T (1975) Gastric operations and glucose homeostasis. II. Glucagon and secretin. Gastroenterology 69: 598–606Google Scholar
  9. Christiansen J (1980) Pancreatic glucagon and gastric acid secretion. Scand J Gastroenterol 15: 257–258PubMedCrossRefGoogle Scholar
  10. Cresto J, Lavine R, Perrino P, Recant L, August G, Hung W (1974) Glucagon antibodies in diabetic patients. Lancet 1: 1165PubMedCrossRefGoogle Scholar
  11. Croughs RJM, Hulsman HAM, Israel DE, Hackeng WHZ, Schopman W (1977) Glucagonoma as part of the polyglandular adenoma syndrome. Am J Med 52: 690–695CrossRefGoogle Scholar
  12. Danielson E, Sehlen R (1974) Transport and oxidation of amino acids and glucose in isolated exocrine mouse pancreas: effects of insulin and pancreozymin. Acta Physiol Scand 91: 557–565CrossRefGoogle Scholar
  13. Debas HT, Hancock RJ, Soon-Shiong P, Smyth HA, Cassim MM (1980) Glucagon therapy in acute pancreatitis: prospective randomized double–blind study. Can J Surg 23: 578–580PubMedGoogle Scholar
  14. DelPrete GF, Tiengo A, Nosadini R, Bottazzo GF, Betterle C, Bersani G (1978) Glucagon secretion in two patients with auto antibodies to glucagon secreting cells. Horm Metab Res 10: 260–261CrossRefGoogle Scholar
  15. Dorner M, Stahl J (1957) Recherches sur le glucagon. II. Relations entre l’hypophyse antérieure et le système alpha–cellulaire du pancréas chez le chien. Rev Fr Etud Clin Biol 2: 118–128Google Scholar
  16. Falkmer S, Ostberg Y (1977) Comparative morphology of pancreatic islets in animals. In: Volk BW, Wellmann KF (eds) The diabetic pancreas. Plenum, New York, p 15Google Scholar
  17. Falkmer S, Patent GJ (1972) Comparative and embryological aspects of the pancreatic islets. In: Steiner DF, Freinkel N (eds) The endocrine pancreas. Williams & Wilkins, Baltimore (Handbook of physiology, Vol 1, p 1 )Google Scholar
  18. Fitz-Patrick D, Patel YC (1981) Antibodies to insulin, pancreatic polypeptide, glucagon, and somatostatin in insulin–treated diabetics. J Clin Endocrinol Metab 52: 948–952PubMedCrossRefGoogle Scholar
  19. Foà PP, Dunbar JC, Klein SP, Levy SH, Malik MA (1980) Reactive hypoglycemia in alpha cell (‘pancreatic’) glucagon deficiency in the adult. JAMA 244: 2281–2285PubMedCrossRefGoogle Scholar
  20. Fujita T, Kobayashi S (1974) The cells and hormones of the GEP endocrine system: the current of studies. In: Fujita T (ed) Gastroentero-pancreatic endocrine system. Williams & Wilkins, Baltimore, p 1Google Scholar
  21. Fujita T, Watanabe Y (1974) The effects of islet hormones upon the exocrine pancreas. In: Fujita T (ed) Gastronteropancreatic endocrine system. Williams & Wilkins, Baltimore, p 164Google Scholar
  22. Glucagon in Human Endocrine and Exocrine Disorders Gerich JE, Schneider V, Dippe SE, Langlois M, Noacco C, Karam JH, Forsham PH (1974) Characterization of the glucagon response to hypoglycemia in man. J Clin Endocrinol Metab 38: 77–82CrossRefGoogle Scholar
  23. Gerich P, Cryer P, Rizza R (1980) Hormonal mechanisms in acute glucose counter regulation: the relative roles of glucagon, epinephrine, growth hormone and Cortisol. Metabolism 29: 1164–1175PubMedCrossRefGoogle Scholar
  24. Giugliano D, Luyckx A, Binder D, Lefebvre P (1979) Comparative effects of metformin and indanorex in the treatment of reactive hypoglycemia. Int J Clin Pharmacol 17: 76–81Google Scholar
  25. Gleeson MH, Bloom SR, Polak JM, Henry K, Dowling RH (1971) Endocrine tumour in kidney affecting small bowel structure, motility and absorptive function. Gut 12: 773–111PubMedCrossRefGoogle Scholar
  26. Gold H, Spector S, Samaan NA, Pearson OH (1968) Effect of growth hormone on carbohydrate metabolism in hypopituitary dwarfs. Metabolism 17: 74–83PubMedCrossRefGoogle Scholar
  27. Goldfine ID, Kirsteins L, Lawrence AM (1972) Excessive glucagon responses to arginine in active acromegaly. Horm Metab Res 4: 97–100PubMedCrossRefGoogle Scholar
  28. Gotlin RW, Silver HK (1970) Neonatal hypoglycemia, hyperinsulinism and absence of pancreatic alpha cells. Lancet 1:1346 Hamaji M (1979) Pancreatic a and cell function in pheochromocytoma. J Clin Endorinol Metab 49: 322–325Google Scholar
  29. Henderson JR (1969) Why are the islets of Langerhans? Lancet 2: 469–470PubMedCrossRefGoogle Scholar
  30. Hökfelt B, Hansson BG, Heding LG, Nilsson KO (1978) Effect of insulin-induced hypogly cemia on the blood levels of catecholamines, glucagon, growth hormone, Cortisol, C-peptide and proinsulin before and during medication with the cardioselective beta receptor blocking agent metoprolol in man. Acta Endocrinol (Copenh) 87: 659–667Google Scholar
  31. Imura H, Ikeda M, Seino Y (1977) Significance of the measurement of plasma insulin and glucagon in the diagnosis of diabetes mellitus. Jpn J Med 16: 55–56CrossRefGoogle Scholar
  32. Kannan V, Nabarro JDN, Cotton PB (1979) Glucagon secretion in chronic pancreatitis. Horm Res 11: 203–212PubMedCrossRefGoogle Scholar
  33. Kanno T, Saito A (1976) The potentiating influences of insulin on pancreozymin-induced hyperpolarization and amylase release in the pancreatic acinar cell. J Physiol (Lond) 261: 505–521Google Scholar
  34. Kollee LA, Monnens LA, Cecjka V, Wilms RM (1978) Persistent neonatal hypoglycemia due to glucagon deficiency. Arch Dis Child 53: 422–424PubMedCrossRefGoogle Scholar
  35. Korc M, Sankaran H, Wong KY, Williams JA, Goldfine ID (1978) Insulin receptors in isolated mouse pancreatic acini. Biochem Biophys Res Commun 84: 293–299PubMedCrossRefGoogle Scholar
  36. Kracht J (1953) Wirkung von Wachstumhormon auf die Langerhans’schen Inseln des Rat–ten Pankreas. Naturwissenschaften 40: 607–608CrossRefGoogle Scholar
  37. Kronborg O, Bulow S, Joergensen PM, Svendsen LB (1980) A randomized doublelind trial of glucagon in treatment of first attack of severe acute pancreatitis without associated biliary disease. Am J Gastroenterol 73: 423–425PubMedGoogle Scholar
  38. Lawrence AM (1966 a) Radioimmunoassay able glucagon levels in man: effects of starvation, hypoglycemia, and glucose administration. Proc Natl Acad Sei USA 55:316–320Google Scholar
  39. Lawrence AM ( 1966 b) Failure of normal glucagon response in the dumping syndrome. Proc annual meeting endocrine society, June, 1966Google Scholar
  40. Lawrence AM (1972) Pancreatic alpha–cell function in miscellaneous clinical disorders. In: Lefebvre PJ, Unger RH (eds) Glucagon, molecular physiology, clinical and therapeutic implications. Pergamon, New York, p 259Google Scholar
  41. Lawrence AM, Abraira C (1977) Glucagon and its clinical significance. Lab Med 8: 21–26Google Scholar
  42. Lawrence AM, Abraira C (1980) Glucagon and diabetes mellitus. In: Podolsky S (ed) Clinical diabetes: modern management. Appleton Century Crofts, New York, p 589Google Scholar
  43. Lawrence AM, Dorsch T (1980) The glucagonoma syndrome. In: Podolsky S, Viswanathan M (eds) Secondary diabetes: the spectrum of the diabetic syndrome. Raven, New York, p 287Google Scholar
  44. Lawrence AM, Hagen TC, Kirsteins L (1972) Propranolol hypoglycemia and impaired glucagon secretion. Clin Res 20: 770Google Scholar
  45. Lawrence AM, Prinz RA, Paloyan E, Kokal WA (1979) Glucagon and insulin in pancreatic exocrine secretions. Lancet 1: 1354PubMedCrossRefGoogle Scholar
  46. Lefebvre P, Luyckx AS, Lecomte MJ (1976) Studies on the pathogenesis of reactive hypoglycemia: role of insulin and glucagon. Horm Metab Res 6 (Suppl.): 91–98PubMedGoogle Scholar
  47. Like A A, Orci L (1972) Embryogenesis of the human pancreatic islets: a light and electron microscopic study. Diabetes 21: 511–534PubMedGoogle Scholar
  48. Liljenquist JE, Mueller GL, Cherrington AD, Keller U, Chiasson JL, Perry JM, Lacy WW, Rabinowitz D (1977) Evidence for an important role of glucagon in the regulation of hepatic glucose production in normal man. J Clin Invest 59: 369–374PubMedCrossRefGoogle Scholar
  49. Lund PK, Goodman RH, Jacobs JW, Habener JF (1980) Glucagon precursors identified by immunoprecipitation of products of cell–free translation of messenger RNA. Diabetes 29: 583–586PubMedCrossRefGoogle Scholar
  50. Mäher TD, Tanenberg RJ, Greenberg BZ, Hoffman JE, Dol RP, Goetz FC (1977) Lack of glucagon response to hypoglycemia in diabetic autonomic neuropathy. Diabetes 26: 196–200PubMedCrossRefGoogle Scholar
  51. Malaisse-Lagae F, Ravazzola M, Robberecht P, Vandermeers A, Malaisse WJ, Orci L (1975) Exocrine pancreas: evidence for topographic partition of secretory function. Science 90: 795–797CrossRefGoogle Scholar
  52. Mallinson CN, Bloom SR, Warin AP, Salmon PR, Cox B (1974) A glucagonoma syndrome. Lancet 2: 1PubMedCrossRefGoogle Scholar
  53. Marco J, Baroja IM, Diaz-Fierros ML (1972) Relationship between insulin and gut glucagon immunoreactivity (GLI) in normal and gastrectomized subjects. J Clin Endocrinol Metab 34: 188–191Google Scholar
  54. McGavran MH, Unger RH, Recant L, Polk HC, Kilo C, Levin ME (1966) A glucagon secreting alpha cell carcinoma of the pancreas. N Engl J Med 274: 1408–1411PubMedCrossRefGoogle Scholar
  55. Medical Research Council Multicentre Trial (1980) Morbidity of acute pancreatitis: the effect of aprotinin and glucagon. Gut 21: 334–339Google Scholar
  56. Merimee TJ, Fineberg SE, McKusick VA, Hall J (1970) Diabetes mellitus and sexual ateliotic dwarfism: a comparative study. J Clin Invest 49: 1096–1102PubMedCrossRefGoogle Scholar
  57. Okuno G, Takenaka H (1977) Pancreatic A–cell function in a patient with Addison’s disease. In: Foä PP, Bajaj JS, Foä NL (eds) Glucagon: its role in physiology and clinical medicine. Springer, New York Heidelberg Berlin, p 111Google Scholar
  58. Paloyan E (1967) Recent developments in the early diagnosis of hyperparathyroidism. Surg Clin North Am 47: 61–69PubMedGoogle Scholar
  59. Paloyan E, Lawrence AM, Straus FHII, Paloyan D, Harper PV, Cummings D (1966) Alpha cell hyperplasia in calcific pancreatitis associated with hyperparathyroidism. JAMA 200: 757–761CrossRefGoogle Scholar
  60. Paloyan E, Paloyan D, Harper PV (1967 a) Glucagon induced hypocalcemia. Metabolism 16: 35–39Google Scholar
  61. Paloyan E, Paloyan D, Harper PV (1967 b) The role of glucagon hypersecretion in the relationship of pancreatitis and hyperparathyroidism. Surgery 62: 167–173Google Scholar
  62. Patzelt C, Tager HS, Carroll RJ, Steiner DF (1979) Identification and processing of proglucagon in pancreatic islets. Nature 282: 260–266PubMedCrossRefGoogle Scholar
  63. Pek S, Fajans SS, Floyd JC, Knopf RF, Prchkow VK, Sherman RM, Weisman PN, Conn JW (1971) Effects upon plasma glucagon of human growth hormone and of dexamethasone in man. Clin Res 19: 482Google Scholar
  64. Pfeiffer FF, Raptis S, Fussganger R (1977) Gastrointestinal hormones and islet function. In: Pfeiffer EF (ed) Gastrointestinal hormones. Springer, Berlin Heidelberg New YorkGoogle Scholar
  65. Pickleman JR, Ernst K, Brown S, Paloyan E (1969) Glucagon–induced hypocalcemia: effect of the thyroid gland. Surg Forum 20: 85PubMedGoogle Scholar
  66. Prinz R, Kokal W, Kirsteins L, Smith M, Lawrence AM, Paloyan E (1978) Presence of high concentrations of glucagon and insulin in pancreatic exocrine secretions. Surg Forum 29: 460–461PubMedGoogle Scholar
  67. Prinz RA, Kirsteins L, Connick E, Paloyan E, Lawrence AM (1980) Insulin and glucagon in human pancreatic exocrine fluid. Horm Metab Res 12: 38–39PubMedCrossRefGoogle Scholar
  68. Prinz RA, Dorsch TR, Lawrence AM (1981) Clinical aspects of glucagon-producing islet-cell tumors. Am J Gastroenterol 76: 125–131PubMedGoogle Scholar
  69. Regan PT, Malagelada JR, Go LLW, Wolf AM (1981) A prospective study of the antisecretory and therapeutic effects of Cimetidine and glucagon in human acute pancreatitis. Mayo Clin Proc 56: 499–503PubMedGoogle Scholar
  70. Rehfeld JF, Heding LG, Holst JJ (1973) Increased gut glucagon as a pathogenetic factor in reactive hypoglycemia. Lancet 1: 116–118PubMedCrossRefGoogle Scholar
  71. Reynolds C, Molnar GD, Jiang N, Jones JD, Taylor WF (1973) Abnormal glucagon response to hypoglycemia in unstable diabetics. Diabetes 22: 327Google Scholar
  72. Robson RH (1980) Glucagon for beta–blocker poisoning. Lancet 1: 1357–1358PubMedCrossRefGoogle Scholar
  73. Rothman S (1925) Über Hauterscheinungen bei bösartigen Geschwulsten Innerer Organe. Ann Dermatol Syphiligr 149: 99–123CrossRefGoogle Scholar
  74. Satake K, Pairent FW, Romero F, Appert HE, Howard JM (1972) The concentration of insulin in pancreatic juice. Surg Gynecol Obstet 134: 589–592PubMedGoogle Scholar
  75. Seino Y, Goto Y, Taminato T, Ikeda M, Imura H (1974) Plasma insulin and glucagon responses in patients with thyroid dysfunction. J Clin Endocrinol Metab 38: 1136–1140PubMedCrossRefGoogle Scholar
  76. Seino Y, Goto Y, Kurahachi H, Sakurai H, Ikeda M, Kadowaki S, Inoue Y, Mori K, Taminato T, Imura H (1977) Alteration of plasma glucagon response to arginine after treatment in patients with diabetes mellitus, Cushing’s syndrome and hypothyroidism. Horm Metab Res 9: 28–32Google Scholar
  77. Shapiro H, Ludewig RM (1978) The effect of glucagon on the exocrine pancreas. Am J Gastroenterol 70: 274–281Google Scholar
  78. Stacpoole PW (1981) The glucagonoma syndrome: clinical features, diagnosis and treatment. Endocrinol Rev 2: 347–361CrossRefGoogle Scholar
  79. Stacpoole PW, Jaspan J, Kasselberg AG, Halter SA, Polonsky K, Gluck FW, Liljenquist JE, Rabin D (1981) A familial glucagonoma syndrome. Am J Med 70: 1017–1026PubMedCrossRefGoogle Scholar
  80. Tewskbury DA, Wyman AJB, Mulholland D, Dumas D (1973) Immunoreactive insulin in human duodenal aspirates. Acta Endocrinol (Copenh) [Suppl] 177: 329–331Google Scholar
  81. Torella R, Giugliano D, Scognamiglio G, Passariello N, Tirello A (1982) Glucagon secretion in patients with hypoparathyroidism: effect of serum calcium on glucagon release. J Clin Endocrinol Metab 54: 229–232PubMedCrossRefGoogle Scholar
  82. Trimble ER, Atkinson AB, Buchanan KD, Hadden DR (1980) Plasma glucagon and insulin concentrations in acromegaly. J Clin Endocrinol Metab 51: 626–631PubMedCrossRefGoogle Scholar
  83. Vance E, Stoll RW, Kitabchi AE, Williams RH, Wood FC (1969) Nesidioblastosis in familial endocrine adenomatosis. JAMA 207: 1682–1689CrossRefGoogle Scholar
  84. Vidnes J, Oyasaeter S (1976) Glucagon deficiency causing severe neonatal hypoglycemia in a patient with normal insulin secretion. Pediatr Res 11: 943–949Google Scholar
  85. Villalpando S, Drash A (1979) Circulating glucagon antibodies in children who have insulin dependent diabetes mellitus. Diabetes 28: 294–299PubMedCrossRefGoogle Scholar
  86. White NH, Skor DA, Cryer PE, Levandoski LA, Bier DM, Santiago JV (1983) Identification of type 1 diabetic patients at increased risk for hypoglycemia during intensive therapy. N Engl J Med 308: 485–491PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1983

Authors and Affiliations

  • A. M. Lawrence

There are no affiliations available

Personalised recommendations